Methoxetamine: From drug of abuse to rapid-acting antidepressant

被引：28

作者：

Coppola, M. ^{[1
]}

Mondola, R. ^{[2
]}

机构：

[1] ASL CN2, Dept Addict, I-12051 Alba, CN, Italy

[2] ASL CN1, Dept Mental Hlth, I-12037 Saluzzo, CN, Italy

来源：

MEDICAL HYPOTHESES | 2012年 / 79卷 / 04期

关键词：

MAJOR DEPRESSIVE DISORDER; D-ASPARTATE ANTAGONIST; RESISTANT BIPOLAR DEPRESSION; STAR-ASTERISK-D; ELECTROCONVULSIVE-THERAPY; ALCOHOL DEPENDENCE; SIGMA-RECEPTORS; CHRM2; GENE; RAT-BRAIN; KETAMINE;

D O I：

10.1016/j.mehy.2012.07.002

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Methoxetamine is a dissociative anaesthetic showing pharmacodynamic similarities with its analogue ketamine, a medication with demonstrated rapid-acting antidepressant effects. Like ketamine and other arylcyclohexylamine compounds, methoxetamine is thought to be both a noncompetitive NMDA receptor antagonist and a dopamine reuptake inhibitor. Furthermore, it acts as an agonist at dopamine D2, serotonin 5HT2, muscarinic cholinergic, sigma-1, opioid mu and k receptors. The hypothesis is that methoxetamine can produce rapid antidepressant effects in patients with resistant and non-resistant unipolar and bipolar depression. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：504 / 507

页数：4

共 63 条

[1]

Advisory Council on the Misuse of Drugs (AMID), 2012, METH

[2] Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and σ1 receptor activation [J].